Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ496,4496,70,49
KB900,79040,43
PKN104,65104,75-0,52
Msft-0,27
IBM-0,58
DCX71,2871,290,39
PFE2,52
14.12.2017 9:20:52
Indexy online
AD Index online
select
AD Index online
 

  • 13.12.2017
Applied Gen Technlg (NASDAQ Cons)
Závěr k 13.12.2017 Změna (%) Změna (USD) Objem obchodů (ks)
3,58 -0,69 -0,03 111 511
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 14.12.2017
Popis společnosti
Obecné informace
Název společnostiApplied Genetic Technologies Corp
TickerAGTC
Kmenové akcie:Ordinary Shares
RICAGTC.O
ISINUS03820J1007
Poslední známé roční výsledky30.6.2017
Poslední známé čtvrtletní výsledky30.9.2017
Počet zaměstnanců k 30.6.2017 72
Akcie v oběhu k 31.10.2017 18 093 235
Počet akcionářů k 30.6.2017 35
MěnaUSD
Kontaktní informace
Ulice14193 Nw 119Th Terrace, Suite #10
MěstoALACHUA
PSČ32615
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon13 864 622 204
Fax13026365454

Business Summary: Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP). As of March 31, 2016, the Company was engaged in developing three discovery programs, targeting three indications based on its adeno-associated virus vector technologies. XLRS is an inherited retinal degenerative disease caused by mutations in the retinoschisis1 (RS1) gene. Achromatopsia is an inherited condition that is associated with visual acuity loss, extreme light sensitivity resulting in daytime blindness, and reduced or complete loss of color discrimination, achromatopsia is caused by mutations in any of several genes. The Company is also developing Alpha-1 Antitrypsin Deficiency (Alpha 1).
Financial Summary: BRIEF: For the three months ended 30 September 2017, Applied Genetic Technologies Corp revenues decreased 13% to $10.3M. Net loss totaled $1.4M vs. income of $3.6M. Revenues reflect Grant and other revenue decrease of 79% to $7K. Net loss reflects Research and Development increase of 49% to $8.3M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from $0.20 to -$0.08.
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Bio Therapeutic Drugs
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in the Physical, Engineering, and Life Sciences
SICCommercial Physical Research



  • Poslední aktualizace: 14.12.2017
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the BoardScott Koenig64
President, Chief Executive Officer, DirectorSusan Washer55
Chief Financial OfficerWilliam Sullivan467.8.20177.8.2017
Senior Vice President, Chief Medical OfficerJeffrey Chulay70
Chief Scientific OfficerMark Shearman551.6.20151.6.2015
Vice president and chief business officerStephen Potter6028.1.201528.1.2015
General CounselAndrew Ashe492.8.20172.8.2017
Chief Medical OfficerMichael Goldstein501.12.20161.12.2016